Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm Before Lead Plaintiff Deadline on August 25, 2025
NEW YORK, NY - June 28, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025 (the 'Class Period').
CLICK HERE TO JOIN THE CASE
If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 25, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
Hims & Hers operates a telehealth platform that connects customers to licensed healthcare professionals and offers a range of both prescription and non-prescription health and wellness products.
On May 20, 2024, the Company announced the addition of GLP-1 injections to its comprehensive weight loss portfolio. Hims & Hers stated that '[p]roviding access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic(R) and Wegovy(R) without navigating the shortages and costs that are currently limiting access to the branded medications.'
On April 29, 2025, Hims & Hers announced the first-step in a long-term collaboration with Novo Nordisk by providing 'a bundled offering of Novo Nordisk's FDA-approved Wegovy(R) on the Hims & Hers platform.'
Then, on June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating the collaboration with Hims & Hers, including that 'direct access to Wegovy(R) will no longer be available' to Hims & Hers, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(R) that put patient safety at risk.' The press release stated that Hims & Hers 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' that the 'FDA has never authorized or approved' according to a report from the Brookings Institute.
Following this news, the price of Hims & Hers stock fell $22.24 per share, over 34%, to close at $41.98 per share on June 23, 2025.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/hims-hers-health-inc/
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Jim Cramer on NVIDIA Stock: 'I Don't See It Tripling From Here'
NVIDIA Corporation (NASDAQ:NVDA) is one of the 11 stocks Jim Cramer put under the microscope recently. The company was mentioned during the episode, and here's what Mad Money's host had to say: 'If the semis became like the oils in 1980, then tech would… account for about 60% of the S&P 500. I think that's unrealistic… I just think we gotta curb our enthusiasm a little bit, and everyone knows I love the sector. It's hard to accept that a stock like NVIDIA, currently the largest company in the world, could double or even triple if Reitzes' (Ben Reitzes, Managing Director and Head of Technology Research at Melius Research) bullish forecast comes to life. A close-up of a colorful high-end graphics card being plugged in to a gaming computer. NVIDIA (NASDAQ:NVDA) develops advanced computing, graphics, and networking technologies. The company provides a wide range of products and software that support data centers, AI, robotics, gaming, virtual computing, and automotive systems, including cloud services and digital twin applications tailored for enterprise AI use. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
23 minutes ago
- Yahoo
Jim Cramer Calls AMD a 'Semi-Meaningful Competitor' to NVIDIA
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the 13 stocks Jim Cramer recently shed light on. During the episode, Cramer called the stock a 'semi-meaningful competitor' to NVIDIA. He said: 'Lately though, we've been seeing AMD, their only semi-meaningful competitor; stock's up like 40 straight points, win[s] a lot of business. Same with Cisco, Arm Holdings. Marvell Tech. Broadcom plays a huge role in these. Vertiv makes power and cooling equipment for the data center. A close up of a complex looking PCB board with several intergrated semiconductor parts. Advanced Micro Devices (NASDAQ:AMD) designs and sells a wide range of semiconductor products, including AI accelerators, microprocessors, GPUs, FPGAs, and adaptive SoCs for applications in computing, graphics, gaming, and data centers. While we acknowledge the potential of AMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Jim Cramer Says Applied Digital is a 'Very Good Spec'
Applied Digital Corporation (NASDAQ:APLD) is one of the 11 stocks Jim Cramer put under the microscope recently. A caller asked for Cramer's thoughts on the company, and in response, he said: 'Okay, this is high-performance computing infrastructure, and high-performance computing is on fire. That company doesn't make any money, but I think it's a very good spec.' An overhead view of a large-scale data center with rows of servers and blinking lights. Applied Digital (NASDAQ:APLD) develops and operates digital infrastructure. The company delivers cloud services and high-performance computing tailored to sectors including artificial intelligence, machine learning, and cryptocurrency mining. It is worth noting that in April, when Cramer was asked about the company, he said: 'I know the company, and it's the kind of thing, we have so many of these digital infrastructure plays. I actually just prefer if you're going to go there, just go buy Salesforce. I'm not kidding. Go buy CRM, I would feel better that way.' While we acknowledge the potential of APLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
